New Test for Early Identification of Cervical Cancer

by: cancercompass

A new cancer diagnosis tool may help detect pre-cancerous cells in the cervix more efficiently than a pap smear, reports Reuters.

Zetiq, an Israeli-based company specializing in cancer diagnostic tools, claims its CellDetect™ technology can detect pre-cancerous cells in 90% of patients.

During recent clinical trials, researchers collected and processed cervical smears from 74 women using a cytology method. Each smear was examined using three methods: staining with the traditional Pap method, HPV testing and finally Zetiq's CellDetect™ technology.

Overall, testing showed Zetiq's CellDetect™ technology to have an average sensitivity of 90%, higher than the sensitivity of a Pap test and similar to an HPV test, and a specifity of 74%, higher than the specifity of an HPV test and similar to a Pap test.

In a company press release, Zetiq officials say the analysis was also conducted by an independent professional.

Discuss this new diagnostic method with other cancer survivors, patients and caregivers on the Cancer Compass Diagnosis Message Boards.